AU9536898A - 4-heteroaryl-tetrahydroquinolines and their use as inhibitors of the holesterin-ester transfer protein - Google Patents

4-heteroaryl-tetrahydroquinolines and their use as inhibitors of the holesterin-ester transfer protein

Info

Publication number
AU9536898A
AU9536898A AU95368/98A AU9536898A AU9536898A AU 9536898 A AU9536898 A AU 9536898A AU 95368/98 A AU95368/98 A AU 95368/98A AU 9536898 A AU9536898 A AU 9536898A AU 9536898 A AU9536898 A AU 9536898A
Authority
AU
Australia
Prior art keywords
tetrahydroquinolines
holesterin
heteroaryl
inhibitors
transfer protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU95368/98A
Other languages
English (en)
Inventor
Hilmar Bischoff
Arndt Brandes
Klaus-Dieter Bremm
Michael Logers
Carsten Schmeck
Delf Schmidt
Gunter Schmidt
Jurgen Stoltefuss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Publication of AU9536898A publication Critical patent/AU9536898A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Quinoline Compounds (AREA)
AU95368/98A 1997-09-18 1998-09-07 4-heteroaryl-tetrahydroquinolines and their use as inhibitors of the holesterin-ester transfer protein Abandoned AU9536898A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19741051 1997-09-18
DE19741051A DE19741051A1 (de) 1997-09-18 1997-09-18 Hetero-Tetrahydrochinoline
PCT/EP1998/005656 WO1999014215A1 (de) 1997-09-18 1998-09-07 4-heteroaryl-tetrahydrochinoline und ihre verwendung als inhibitoren des cholesterin-ester-transfer-proteins (ctep)

Publications (1)

Publication Number Publication Date
AU9536898A true AU9536898A (en) 1999-04-05

Family

ID=7842737

Family Applications (1)

Application Number Title Priority Date Filing Date
AU95368/98A Abandoned AU9536898A (en) 1997-09-18 1998-09-07 4-heteroaryl-tetrahydroquinolines and their use as inhibitors of the holesterin-ester transfer protein

Country Status (11)

Country Link
US (4) US6387929B1 (enExample)
EP (1) EP1017692B1 (enExample)
JP (1) JP2001516757A (enExample)
AT (1) ATE260910T1 (enExample)
AU (1) AU9536898A (enExample)
DE (2) DE19741051A1 (enExample)
DK (1) DK1017692T3 (enExample)
ES (1) ES2216316T3 (enExample)
HN (1) HN1998000143A (enExample)
PT (1) PT1017692E (enExample)
WO (1) WO1999014215A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
DE19741051A1 (de) * 1997-09-18 1999-03-25 Bayer Ag Hetero-Tetrahydrochinoline
US6489366B1 (en) 1998-12-23 2002-12-03 G. D. Searle, Llc Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
PT1404300E (pt) 2001-06-22 2009-11-09 Bend Res Inc Composições farmacêuticas de dispersões de fármacos e polímeros neutros
EP1269994A3 (en) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
CA2448825C (en) 2001-06-22 2009-08-11 Pfizer Products Inc. Pharmaceutical compositions of adsorbates of amorphous drug
DE10148436A1 (de) * 2001-10-01 2003-04-17 Bayer Ag Tetrahydrochinoline
US6817530B2 (en) 2001-12-18 2004-11-16 Digimarc Id Systems Multiple image security features for identification documents and methods of making same
US7202247B2 (en) 2001-12-19 2007-04-10 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
WO2003053368A2 (en) 2001-12-19 2003-07-03 Atherogenics, Inc. Chalcone derivatives and their use to treat diseases
US7728048B2 (en) 2002-12-20 2010-06-01 L-1 Secure Credentialing, Inc. Increasing thermal conductivity of host polymer used with laser engraving methods and compositions
US6852753B2 (en) 2002-01-17 2005-02-08 Pharmacia Corporation Alkyl/aryl hydroxy or keto thiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake
EP1469832B2 (en) 2002-02-01 2016-10-26 Bend Research, Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
AR038375A1 (es) 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
US7824029B2 (en) 2002-05-10 2010-11-02 L-1 Secure Credentialing, Inc. Identification card printer-assembler for over the counter card issuing
BR0317521A (pt) 2002-12-20 2005-11-16 Pfizer Prod Inc Formas de dosagem compreendendo um inibidor da cetp e um inibidor da redutase hmg-coa
PT1603553E (pt) 2003-03-17 2012-02-03 Japan Tobacco Inc Composições farmacêuticas de inibidores de cetp
US7225991B2 (en) 2003-04-16 2007-06-05 Digimarc Corporation Three dimensional data storage
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
JP2007501218A (ja) 2003-08-04 2007-01-25 ファイザー・プロダクツ・インク 非晶質薬物の吸着物および親油性ミクロ相形成物質の医薬組成物
CN103330703A (zh) * 2003-09-26 2013-10-02 日本烟草产业株式会社 抑制残余脂蛋白产生的方法
US7615212B2 (en) * 2004-02-26 2009-11-10 Baylor Research Institute Compositions and methods for the systemic treatment of arthritis
US8127137B2 (en) 2004-03-18 2012-02-28 Digimarc Corporation Watermark payload encryption for media including multiple watermarks
EP1814554A1 (en) * 2004-10-25 2007-08-08 Cytokinetics, Inc. Certain compounds, compositions, and methods
WO2006065842A2 (en) * 2004-12-13 2006-06-22 Synta Pharmaceuticals Corp. 5,6,7,8-tetrahydroquinolines and related compounds and uses thereof
US20080194609A1 (en) * 2004-12-18 2008-08-14 Bayer Heathcare Ag Chemical Compound and Its Use
BRPI0519602A2 (pt) * 2004-12-18 2009-02-25 Bayer Healthcare Ag derivados de tetrahidroquinolina substituÍdos com 4-cicloalquila e seu uso como medicamento
US8617604B2 (en) 2005-02-03 2013-12-31 Bend Research, Inc. Pharmaceutical compositions with enhanced performance
WO2006098394A1 (ja) * 2005-03-14 2006-09-21 Japan Tobacco Inc. 脂質吸収抑制方法および脂質吸収抑制剤
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
KR20080059233A (ko) 2005-10-21 2008-06-26 노파르티스 아게 레닌 억제제, 및 항이상지질혈증제 및/또는 항비만제의조합물
DE102006012548A1 (de) 2006-03-18 2007-09-20 Bayer Healthcare Ag Substituierte Chromanol-Derivate und ihre Verwendung
NZ587748A (en) 2008-03-05 2012-01-12 Boehringer Ingelheim Int Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
WO2010075069A1 (en) 2008-12-16 2010-07-01 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
WO2010075068A1 (en) 2008-12-16 2010-07-01 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
MA34007B1 (fr) 2010-02-19 2013-02-01 Boehringer Ingelheim Int Derives de pyridine tricycliques medicaments contenant ces composes leur utilisation et leur procede de preparation
US9187450B2 (en) * 2010-07-09 2015-11-17 Daiichi Sankyo Company, Limited Substituted pyridine compound
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
EP2760868B1 (en) 2011-08-17 2018-04-25 Boehringer Ingelheim International GmbH Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation
CA2860601C (en) * 2012-01-06 2016-07-05 Daiichi Sankyo Company, Limited Acid addition salt of substituted pyridine compound
US20230227410A1 (en) * 2022-01-17 2023-07-20 King Abdulaziz University Tetrahydroquinoline derivatives and a process of preparation thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169857A (en) 1988-01-20 1992-12-08 Bayer Aktiengesellschaft 7-(polysubstituted pyridyl)-hept-6-endates useful for treating hyperproteinaemia, lipoproteinaemia or arteriosclerosis
CA1336714C (en) 1987-08-20 1995-08-15 Yoshihiro Fujikawa Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis
DE68918713T2 (de) 1988-01-18 1995-03-16 Toshiba Kawasaki Kk Interne Pumpe für Kernreaktor.
NO177005C (no) * 1988-01-20 1995-07-05 Bayer Ag Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
DE19709125A1 (de) 1997-03-06 1998-09-10 Bayer Ag Substituierte Chinoline
DE19741051A1 (de) * 1997-09-18 1999-03-25 Bayer Ag Hetero-Tetrahydrochinoline

Also Published As

Publication number Publication date
ATE260910T1 (de) 2004-03-15
EP1017692A1 (de) 2000-07-12
US7192971B2 (en) 2007-03-20
DE59810922D1 (de) 2004-04-08
EP1017692B1 (de) 2004-03-03
US6958346B2 (en) 2005-10-25
ES2216316T3 (es) 2004-10-16
DE19741051A1 (de) 1999-03-25
JP2001516757A (ja) 2001-10-02
PT1017692E (pt) 2004-06-30
US6387929B1 (en) 2002-05-14
US20020062024A1 (en) 2002-05-23
US20070142420A1 (en) 2007-06-21
DK1017692T3 (da) 2004-07-12
US20060069112A1 (en) 2006-03-30
HN1998000143A (es) 1999-04-09
WO1999014215A1 (de) 1999-03-25

Similar Documents

Publication Publication Date Title
AU9536898A (en) 4-heteroaryl-tetrahydroquinolines and their use as inhibitors of the holesterin-ester transfer protein
AU7585598A (en) Raf kinase inhibitors
AU9744298A (en) Substituted tetrahydronaphthaline and analogous compounds
AU5799294A (en) Isoxazole-4-carboxamides and hydroxy-alkylidenecyanoacetamides, pharmaceuticals containing these compounds and their use
ZA99550B (en) Potassium channel inhibitors.
AU678814B2 (en) Benzofuranyl- and -thiophenyl-alkanecarboxyclic acid derivatives
AU5624699A (en) Use of 5ht-6 antagonists
AU2002213336A1 (en) Substituted heterocyclic compounds for treating multidrug resistance
NZ513629A (en) C-21 modified epothilones
TR199902626T2 (xx) Enflamasyon tedavisi i�in ikameli benzopiran t�revleri.
MY131298A (en) 5-heteroyl indole derivatives
AU2675095A (en) Indol derivatives useful for the treatment of migraine, composition and utilization
CA2199117A1 (en) Compounds and methods for the treatment of cancer
IL112539A0 (en) Pyrimidine derivatives and their preparation
IL128205A0 (en) Potassium channel inhibitors and pharmaceutical compositions containing the same
BG102616A (en) Substituted aza- and diazacycloheptane and cyclooctane derivatives and their application
AU6337999A (en) Core-extended perylene bisimides
ZA9710796B (en) Oxyiminopregnanecarbolactones.
BG103310A (en) Benzonaphthyridins as bronchial therapeutical means
BG103096A (en) Thrombin inhibitors
TR200001102T2 (tr) İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları.
AU4714297A (en) Metalloproteinase inhibitors
IL140768A0 (en) Chemotaxis-inhibiting protein of staphylococcus (chips) and its use
CA2298820A1 (en) The use of 1,3,4,6-tetrahydroxy-helianthrone and its derivatives in photodynamic therapy and certain such novel derivatives
AU3251597A (en) Composition and methods for modulating the length of telomeres

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase